The immune landscape of gliomas is modulated by IDH1/2 genetic alterations, notably, PD-L1 expression is substantially decreased in mutated tumors, providing a mechanistic basis for immune checkpoint inhibitors (ICIs) in IDH1/2 wild-type (wt) patients. The gene discussed is IDH1; the disease is central nervous system cancer.